A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
NCT ID: NCT03820726
Last Updated: 2023-09-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
435 participants
INTERVENTIONAL
2019-04-16
2022-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Nintedanib in Real World in China
NCT05676112
Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis
NCT03047031
Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
NCT00071461
Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT07181382
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
NCT02802345
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nintedanib
Patients taking 150 milligram (mg) bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib 150 mg bid in this extension trial. Patients taking 100 mg bid blinded trial medication (active drug or placebo) at the end of INBUILD® started treatment with nintedanib in this extension trial either at 100 mg bid or at an increased dose of 150 mg bid at the discretion of the investigator orally as soft gelatine capsule, twice daily (bid), together with a glass of water (\~250 mL), in a dose interval of 12 hours. With an optional dose reduction to 100 mg bid temporarily or permanently to manage adverse events (AEs). The treatment had a duration of 96 weeks or until nintedanib was made available to the patients outside of the clinical trial. Treatment was stopped if any reason for withdrawal was met.
Nintedanib
Bid
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nintedanib
Bid
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
* Women of childbearing potential (WOCBP)1 must continue to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly, as well as one barrier method, for 28 days prior to and 3 months after nintedanib administration. A list of contraception methods meeting these criteria is provided in the patient information
Exclusion Criteria
* Patient not compliant in parent trial (INBUILD®), with trial medication or trial visits, according to investigator's judgement.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama at Birmingham
Birmingham, Alabama, United States
University of California Los Angeles
Los Angeles, California, United States
University of California Davis
Sacramento, California, United States
National Jewish Health
Denver, Colorado, United States
Yale University School of Medicine
New Haven, Connecticut, United States
Pulmonary and Sleep of Tampa Bay
Brandon, Florida, United States
University of Florida College of Medicine
Jacksonville, Florida, United States
Emory University
Atlanta, Georgia, United States
University of Chicago
Chicago, Illinois, United States
Loyola University Medical Center
Maywood, Illinois, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Pulmonary and Critical Care Associates of Baltimore
Towson, Maryland, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Henry Ford Health System
Detroit, Michigan, United States
Mayo Clinic, Rochester
Rochester, Minnesota, United States
The Lung Research Center, LLC
Chesterfield, Missouri, United States
Creighton University
Omaha, Nebraska, United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, United States
Icahn School of Medicine at Mount Sinai
New York, New York, United States
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York, United States
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
The Oregon Clinic
Portland, Oregon, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Baylor University Medical Center
Dallas, Texas, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Diagnostics Research Group
San Antonio, Texas, United States
Medical Arts and Research Center (MARC)
San Antonio, Texas, United States
University of Utah Health Sciences Center
Salt Lake City, Utah, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States
Centro Dr. Lazaro Langer S.R.L
Alberdi Sur, , Argentina
Centro de Investigaciones Metabólicas (CINME)
C.a.b.a, , Argentina
CEMER-Centro Medico De Enfermedades Respiratorias
Florida, , Argentina
INSARES
Mendoza, , Argentina
Instituto Médico de la Fundación Estudios Clínicos
Rosario, , Argentina
ULB Hopital Erasme
Brussels, , Belgium
UZ Leuven
Leuven, , Belgium
Centre Hospitalier Universitaire de Liège
Liège, , Belgium
Yvoir - UNIV UCL de Mont-Godinne
Yvoir, , Belgium
Winnipeg Clinic
Winnipeg, Manitoba, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Toronto General Hospital
Toronto, Ontario, Canada
CHUS Fleurimont
Sherbrooke, Quebec, Canada
Hospital Clínico Reg. de Concepción "Dr. G. Grant Benavente"
Concepción, , Chile
Instituto Nacional del Tórax
Providencia, Santiago de Chile, , Chile
Centro de Investigación del Maule
Talca, , Chile
Peking Union Medical College Hospital
Beijing, , China
Nanjing Drum Tower Hospital
Nanjing, , China
The First Hospital of China Medical University
Shenyang, , China
HOP Avicenne
Bobigny, , France
HOP Louis Pradel
Bron, , France
HOP Côte de Nacre
Caen, , France
CHRU Lille
Lille, , France
HOP Nord
Marseille, , France
HOP Arnaud de Villeneuve
Montpellier, , France
HOP Pasteur
Nice, , France
HOP Bichat
Paris, , France
HOP Maison Blanche
Reims, , France
HOP Pontchaillou
Rennes, , France
HOP Civil
Strasbourg, , France
HOP Bretonneau
Tours, , France
Universitätsklinikum Bonn AöR
Bonn, , Germany
Fachkrankenhaus Coswig GmbH
Coswig, , Germany
Klinik Donaustauf
Donaustauf, , Germany
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, , Germany
Medizinische Hochschule Hannover
Hanover, , Germany
Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg
Heidelberg, , Germany
Petrus-Krankenhaus
Wuppertal, , Germany
A.O.U. Policlinico Vittorio Emanuele
Catania, , Italy
Ospedale "G.B. Morgagni - L. Pierantoni" ausl forli
Forlì, , Italy
Azienda Ospedaliera Policlinico di Modena
Modena, , Italy
A.O. San Gerardo di Monza
Monza, , Italy
Poli Univ A. Gemelli
Roma, , Italy
A.O.U. Senese Policlinico Santa Maria alle Scotte
Siena, , Italy
Tosei General Hospital
Aichi, Seto, , Japan
Kurume University Hospital
Fukuoka, Kurume, , Japan
Sapporo Medical University Hospital
Hokkaido, Sapporo, , Japan
National Hospital Organization Himeji Medical Center
Hyogo, Himeji, , Japan
Kobe City Medical Center General Hospital
Hyogo, Kobe, , Japan
Ibarakihigashi National Hospial
Ibaraki, Naka-gun, , Japan
Kanagawa Cardiovascular and Respiratory Center
Kanagawa, Yokohama, , Japan
Saiseikai Kumamoto Hospital
Kumamoto, Kumamoto, , Japan
Tohoku University Hospital
Miyagi, Sendai, , Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
Osaka, Sakai, , Japan
Osaka Medical College Hospital
Osaka, Takatsuki, , Japan
Hamamatsu University Hospital
Shizuoka, Hamamatsu, , Japan
Tokushima University Hospital
Tokushima, Tokushima, , Japan
Tokyo Medical and Dental University Hospital
Tokyo, Bunkyo-ku, , Japan
Toranomon Hospital
Tokyo, Minato-ku, , Japan
JR Tokyo General Hospital
Tokyo, Shibuya-ku, , Japan
Center Hospital of the National Center for Global Health and Medicine
Tokyo, Shinjuku-ku, , Japan
University Clinical Center, Gdansk
Gdansk, , Poland
Leszek Giec Upper-Silesian Med.Cent.Silesian Med.Univ.
Katowice, , Poland
Norbert Barlicki University Clinical Hospital No.1, Lodz
Lodz, , Poland
Nat.Instit.of Tuberculosis&LungDiseases,Outpat.Clin,warszawa
Warsaw, , Poland
Clinical Hospital No. 1, n.a. Prof. Szyszko from Silesian MA
Zabrze, , Poland
Res.Inst.-Compl.Iss.Cardi.Dis.
Kemerovo, , Russia
Central Scientific Research Insitute of Tuberculosis
Moscow, , Russia
Moscow 1st State Med.Univ.n.a.I.M.Sechenov
Moscow, , Russia
1stPavlov St.Med.Univ.St.-Petersburg Res.Inst.
Saint Petersburg, , Russia
Emergency Clinical Hospital n. a. N. V. Solovyev, Yaroslavl
Yaroslavl, , Russia
The Catholic University of Korea, Bucheon St.Mary's Hospital
Bucheon-si, , South Korea
Seoul National University Bundang Hospital
Seongnam, , South Korea
Asan Medical Center
Seoul, , South Korea
Hospital Santa Creu i Sant Pau
Barcelona, , Spain
Hospital de Galdakao
Galdakao, , Spain
Hospital de Bellvitge
L'Hospitalet de Llobregat, , Spain
Hospital La Princesa
Madrid, , Spain
Hospital Central de Asturias
Oviedo, , Spain
Hospital Son Espases
Palma de Mallorca, , Spain
Hospital de Canarias
San Cristóbal de La Laguna, , Spain
Hospital Virgen del Rocío
Seville, , Spain
Royal Infirmary of Edinburgh
Edinburgh, , United Kingdom
St James's University Hospital
Leeds, , United Kingdom
Royal Brompton Hospital
London, , United Kingdom
Wythenshawe Hospital
Manchester, , United Kingdom
University Hospital Llandough
Penarth, , United Kingdom
Royal Stoke University Hospital
Stoke-on-Trent, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wuyts WA, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Song JW, Miede C, Dumistracel M, Coeck C, Cottin V. Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON. Lung. 2025 Jan 9;203(1):25. doi: 10.1007/s00408-024-00778-z.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-000525-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1199-0248
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.